Rethinking Executive Pay

Authored by David Hobbs, Senior Editor, Criticaleye

As the economic environment tightens, the pressure on remuneration committees looks set to intensify. Katherine Savage, People Advisory Services Partner at EY tells David Hobbs how they can create pay policies that are fair, balanced and reflective of a company’s performance.

Key points include:

- The need for executive pay restraint in the current climate
- Ensuring senior rewards are aligned with that of the wider workforce
- The restriction on businesses that received government support
- The view from regulators and central banks
- The potential for the pandemic to accelerate change around ESG

Share this with your Community




Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

BLOG | Alignment at the Top

At our recent Growth Company Retreat, one theme came through consistently across discussions with executives and non-executive directors of high growth business leaders: strategy alone is not enough, alignme...


Criticaleye Asia Podcast - Chairing for Impact: Leadership Lessons from Ray Ferguson, Global Board Chair

In this episode, Yu-Wen Hsiao, Marketing and Communications Manager, APAC at Criticaleye, speaks with Ray Ferguson, Global Board Chair and seasoned international banker, shares his perspective on how CEOs and Boards ...


Click here to download this insight

BLOG | Unlocking Value as CPO

CPOs are navigating an era of rapid disruption: shaping workforce strategy, managing an evolving talent landscape, meeting rising expectations from the Board and acting as architects of organisational transformation....


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 196




Worldpay Lightsource bp Legal & General Rolls-Royce AlixPartners Drax Group plc British Land Canaccord Genuity Group Inc LACE Partners Hitachi Solutions Aldermore Group NatWest Group London Stock Exchange Group Mayborn Group GlaxoSmithKline plc E.ON UK NATS